Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Lenalidomide maintenance in MM: data update

Graham Jackson • 7 Dec 2019
ASH 2019
Multiple Myeloma Lenalidomide
Myeloma XI

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, outlines the updated data on lenalidomide maintenance therapy in multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Graham Jackson

Myeloma treatment updates: a UK perspective
Myeloma treatment updates: a UK perspective
Graham Jackson • 14 Jun 2022
The management of patients with lenalidomide-refractory multiple myeloma in the UK
1:00
The management of patients with lenalidomide-refractory multiple myeloma in the UK
Graham Jackson • 30 Jan 2025
Recent approvals and updates impacting myeloma treatment in the UK
1:45
Recent approvals and updates impacting myeloma treatment in the UK
Graham Jackson • 30 Jan 2025
Unmet needs that remain for patients with myeloma in the UK
1:19
Unmet needs that remain for patients with myeloma in the UK
Graham Jackson • 30 Jan 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Graham Jackson • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Graham Jackson • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Graham Jackson • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Graham Jackson • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals